The use of antiestrogens tamoxifen and nafoxidine in the treatment of human breast cancer in correlation with estrogen receptor values.A phase II study
- 1 March 1978
- Vol. 41 (3) , 797-802
- https://doi.org/10.1002/1097-0142(197803)41:3<797::aid-cncr2820410303>3.0.co;2-7
Abstract
Twenty-five patients with measurable metastatic breast cancer and assays for estrogen receptor (ER) were studied. Of the 16 ER positive patients on antiestrogen therapy, one had complete disappearance of all tumor for seven months and seven patients had more than 50% reduction in their measurable tumor for an average duration of 8.8 months. Seven other ER positive patients had stabilization of their tumors for an average interval of 8.4 months. Only one of the 16 ER positive patients progressed promptly. Conversely there was only one partial response in the nine ER negative patients and only two ER negative patients had stabilization of disease. Six out of nine ER negative patients progressed promptly. Correlation existed between the duration of response and absolute estrogen receptor level of the tumor. There may be a positive correlation between the response to antiestrogen therapy and response to endocrine ablation but prospective studies must be done to further define the role of antiestrogens in this regard.This publication has 26 references indexed in Scilit:
- Nafoxidine–-an antiestrogen for the treatment of breast cancerCancer, 1976
- LevoDopa Test and Estrogen Receptor Assay in Prognosticating Responses of Patients with Advanced Cancer of the Breast to Endocrine TherapyAnnals of Surgery, 1976
- Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study.BMJ, 1975
- Oestrogen receptors in breast cancer: a changing concept.BMJ, 1975
- Antioestrogens in Treatment of Breast Cancer: Value of Nafoxidine in 52 Advanced CasesBMJ, 1974
- Clinical trial of nafoxidine, an oestrogen antagonist in advanced breast cancerPublished by Elsevier ,1972
- SITE OF ACTION OF CLOMIPHENE AND ITS USE AS A TEST OF PITUITARY FUNCTIONBJOG: An International Journal of Obstetrics and Gynaecology, 1971
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971
- Inhibition of DMBA-Induced Mammary Carcinogenesis in the Rat by 2-Br-α-Ergocryptine (CB 154), An Inhibitor of Prolactin Secretion, and by Nafoxidine (U-11, 100 A), an Estrogen AntagonistGynecologic and Obstetric Investigation, 1971
- PREVENTION OF IMPLANTATION IN RATS BY I.C.I. 46,474: ROLE OF HISTAMINEJournal of Endocrinology, 1967